Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Viacoram | perindopril arginine / amlodipine | Hypertension, essential | Reimburse with clinical criteria and/or conditions | Complete | ||
Perjeta Herceptin Combo Pack | Pertuzumab | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Perjeta or Perjeta-Herceptin Combo Pack | Pertuzumab | Neoadjuvant Breast Cancer | Do not reimburse | Complete | ||
Perjeta | pertuzumab | Early stage breast cancer | Do not reimburse | Complete | ||
Perjeta-Herceptin Combo Pack | Pertuzumab-Trastuzumab Combo Pack | Early Breast Cancer | Do not reimburse | Complete | ||
Grastek | Phleum pratense | Allergic rhinitis | Do not list | Complete | ||
Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | List with criteria/condition | Complete | ||
Esbriet | Pirfenidone | Idiopathic pulmonary fibrosis | Do not list | Complete | ||
Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete | ||
Mozobil | Plerixafor | Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma | Do not list | Complete |